COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis (ESBAM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02556866
Recruitment Status : Terminated (lack of recruitment)
First Posted : September 22, 2015
Last Update Posted : March 18, 2019
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
Multicenter randomized double-blind study comparing the efficacy and safety of rituximab in combination with corticosteroids to corticosteroids plus placebo in the treatment of non-infectious active mixed cryoglobulinemia vasculitis.

Condition or disease Intervention/treatment Phase
Cryoglobulinemia Systemic Vasculitis Drug: rituximab Drug: Prednisone Drug: Placebo Phase 2

Detailed Description:

Cryoglobulinemia are responsible for systemic vasculitis, and the most frequently targeted organs are the skin, joints, kidneys and peripheral nervous system. Cryoglobulinemia vasculitis are associated with significant morbidity and mortality, and require therapeutic intervention. Management of non-infectious mixed cryoglobulinemia vasculitis is based on corticosteroids, plasma exchange, and/or immunosuppressants. These treatments are associated with frequent side effects. To date, no study has evaluated the efficacy and safety of these different therapeutic options, explaining the lack of recommendations.

Rituximab, a monoclonal antibody directed against CD20, has emerged as a novel therapeutic option in B-cell related disorders. Data from the French AutoImmunity and Rituximab (AIR) registry recently reported the positive effect of rituximab in non-infectious mixed cryoglobulinemia vasculitis. More recently, the multidisciplinary national French CryoVas survey also suggested a significant superiority of the combination corticosteroid plus rituximab compared to the corticosteroids alone in terms of complete clinical and immunological responses and corticosteroid sparing. However, no randomized controlled data addressing this issue has been published to date.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Multicenter Randomized Double-blind Study Comparing the Efficacy and Safety of Rituximab in Combination With Corticosteroids to Corticosteroids Plus Placebo in the Treatment of Non-infectious Active Mixed Cryoglobulinemia Vasculitis
Actual Study Start Date : July 17, 2015
Actual Primary Completion Date : May 31, 2018
Actual Study Completion Date : May 31, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Steroids Vasculitis

Arm Intervention/treatment
Experimental: rituximab
Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
Drug: rituximab
Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.

Drug: Prednisone
Placebo Comparator: placebo
Prednisone treatment plus placebo administered by slow intravenous infusion at day 1 (D1), D8, D15 and D22.
Drug: Prednisone
Drug: Placebo

Primary Outcome Measures :
  1. Complete clinical response of vasculitis symptoms (yes-no, i.e. success-failure) with corticosteroid withdrawal (prednisone at 0 mg/day) at week (W) 24, with at least one clinical response at W4 [ Time Frame: Week 24 ]
    The complete clinical response is defined by the remission of all affected organs involved at baseline and the absence of clinical relapse.

Secondary Outcome Measures :
  1. Partial clinical response [ Time Frame: Week 24 ]
    Partial clinical response defined by an improvement of at least half of organ impairments present at baseline

Other Outcome Measures:
  1. Evolution of cryoglobulinemia (positive or negative) [ Time Frame: Week 24 ]
  2. Evolution of C4 complement fraction (mg/L) [ Time Frame: Week 24 ]
  3. Rate of early failures [ Time Frame: Week 4 ]
  4. Occurrence of clinical relapse [ Time Frame: up to Week 48 ]
    Clinical relapse is defined by de novo appearance or reappearance of a manifestation attributable to cryoglobulinemia vasculitis during 48 weeks of follow-up,

  5. Cumulative dose of prednisone [ Time Frame: Week 24 ]
  6. quality of life [ Time Frame: Day 1 ]
    evolution of quality of life will be assessed by the score SF36

  7. quality of life [ Time Frame: Week 4 ]
    evolution of quality of life will be assessed by the score SF36

  8. quality of life [ Time Frame: Week 8 ]
    evolution of quality of life will be assessed by the score SF36

  9. quality of life [ Time Frame: Week 16 ]
    evolution of quality of life will be assessed by the score SF36

  10. quality of life [ Time Frame: Week 24 ]
    evolution of quality of life will be assessed by the score SF36

  11. quality of life [ Time Frame: Week 36 ]
    evolution of quality of life will be assessed by the score SF36

  12. quality of life [ Time Frame: Week 48 ]
    evolution of quality of life will be assessed by the score SF36

  13. quality of life at relapse [ Time Frame: up to Week 48 ]
    quality of life at relapse will be assessed by the score SF36

  14. Infusion related reactions [ Time Frame: up to Week 4 ]
    hypersensitivity reaction rate such as fall in blood pressure, bronchospasm, … due to rituximab or placebo infusions (included also reaction occurring after the end of infusion),

  15. Rate of infections (severe or not) and other complications related to corticosteroids [ Time Frame: up to Week 48 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The patient must be at least 18 years of age or older, without any upper age limit
  2. Patient informed and agreed to participate, and gave informed consent,
  3. Patient with active cryoglobulinemia vasculitis define by positive cryoglobulinemia and a clinically active vasculitis with skin, joint, renal, peripheral nerve, central neurological, digestive, pulmonary and/or cardiac involvement (no histological evidence needed if presence of purpura demonstrated),
  4. Patient with primary Sjögren's syndrome, systemic lupus erythematosus, or another auto-immune disease, or B-cell non-Hodgkin lymphoma (with cryoglobulinemia as the only therapeutic indication), or essential mixed cryoglobulinemia,
  5. Naive or relapsing patients, without modification (initiation or increase) of immunosuppressive therapy in the month prior the inclusion,
  6. For women of child bearing age: negative pregnancy test during the inclusion, and effective contraception during the period of 12 months after the latest rituximab infusion or placebo,
  7. Patients with severe vasculitis must be treated in the 15 days prior inclusion by 3 bolus of methylprednisolone (15 mg/kg/d) AND 3 to 7 plasma exchanges (exchange volume of 60 ml/kg/session).

Exclusion Criteria:

  1. Patient with a medium and small size vessels vasculitis unrelated to cryoglobulinemia (granulomatous with polyangiitis (Wegener's disease), microscopic polyangiitis, eosinophilic granulomatous with polyangiitis (Churg-Strauss syndrome), polyarteritis nodose, IgA vasculitis, hypersensitivity vasculitis, infectious vasculitis, hypocomplementemic urticarial vasculitis),
  2. Patient with a large size vessels vasculitis,
  3. Patient with non active cryoglobulinemia vasculitis,
  4. Patient with immunosuppressive therapy introduced or increased in the month prior to the inclusion,
  5. Patients receiving corticosteroid therapy > 0.5 mg/kg/d for more than one month before the inclusion or > 1 mg/kg/d for more than two weeks before the inclusion,
  6. Patient who had received rituximab therapy within the 12 months before the inclusion,
  7. Pregnancy in progress or needed , breast feeding,
  8. HIV-positive status,
  9. Patient with active hepatitis B or C infection,
  10. HBs Ag-positive and/or HBV DNA detectable in the blood*,
  11. Patients with known hypersensitivity reaction to the active substance or any of the excipients, or to murine proteins,
  12. Contraindication to rituximab,
  13. Active infections at screening,
  14. Patient in guardianship,
  15. Patient already included in a biomedical research protocol,
  16. No social security scheme (Beneficiaries or eligible),
  17. History of cancer during the last 3 years before inclusion, including solid tumors, hematological malignancies (except lymphoproliferative disorder associated with the mixed cryoglobulinemia vasculitis), and carcinoma in situ (except basal cell and squamous cell carcinoma of the skin that have been treated or excized and cured)"

    • If the hepatitis B core antibody (anti-HBc) is positive, the benefit/risk will be evaluated by an hepatologist before inclusion, and patient, if enrolled, will be monitored until the end of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02556866

Layout table for location information
Pitié Salpetriere Hospital
Paris, France, 75013
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Layout table for investigator information
Principal Investigator: Patrice CACOUB, MD, PhD Assistance Publique - Hôpitaux de Paris
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris Identifier: NCT02556866    
Other Study ID Numbers: P120122
2013-000844-24 ( EudraCT Number )
First Posted: September 22, 2015    Key Record Dates
Last Update Posted: March 18, 2019
Last Verified: March 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Systemic Vasculitis
Vascular Diseases
Cardiovascular Diseases
Hemostatic Disorders
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal